Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide for Impaired Hypoglycaemic Awareness in Type 1 Diabetes
NCT02735031Phase 3Completed
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2017
- Primary completion
- Mar 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing Exenatide with Placebo (2 arms). Primary endpoint: Symptom score in response to insulin-induced hypoglycaemia at 30 minutes. Started Feb 2017; status: completed.
02
Drugs
exenatide
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02735031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02735031.